| Post |
| Pre |
| LA |
|---|
| - |
| - |
| ME 1 | ME 2 | ME 3 | ME 4 | ME 5 | ME 6 | ME 7 | ME 8 | ME 9 | ME 10 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 1 | 19 | 38.5 | 81.7 | 140.2 |
| - | - | - | - | - | - | - | 1 | 9 | 40.7 | 50.7 |
| Post |
| Pre |
| LO 1 | LO 2 | LO 3 | LO 4 | LO 5A | LO 5B | LO 6 | Total |
|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | - | - |
| AME |
|---|
| - |
| - |
| Post |
| Pre |
| LOP 1 | LOP 2 | LOP 3 | LOP 4 | Total |
|---|---|---|---|---|
| 1 | 2 | - | 5 | - |
| - | - | - | - | - |
| central brain |
|---|
| - |
| - |

| ROI Name | ∑ In | % In | log ratio | ∑ Out | % Out |
|---|---|---|---|---|---|
| ME(L) | 342 | 91.7% | -1.28 | 141 | 88.7% |
| Optic-unspecified(L) | 22 | 5.9% | -0.29 | 18 | 11.3% |
| LOP(L) | 9 | 2.4% | -inf | 0 | 0.0% |
| upstream partner | # | NT | conns T4_unclear | % In | CV |
|---|---|---|---|---|---|
| Mi1 (L) | 16 | ACh | 39.7 | 32.7% | 0.9 |
| Mi9 (L) | 10 | Glu | 12.3 | 10.2% | 0.9 |
| Tm3 (L) | 6 | ACh | 10.3 | 8.5% | 0.6 |
| Mi4 (L) | 10 | GABA | 8.7 | 7.1% | 0.6 |
| TmY15 (L) | 6 | GABA | 8.3 | 6.9% | 0.5 |
| CT1 (R) | 1 | GABA | 7 | 5.8% | 0.0 |
| C3 (L) | 11 | GABA | 6 | 4.9% | 0.5 |
| T4d (L) | 7 | ACh | 5 | 4.1% | 0.5 |
| Y12 (L) | 2 | Glu | 4 | 3.3% | 0.7 |
| T4c (L) | 7 | ACh | 4 | 3.3% | 0.3 |
| TmY19a (L) | 2 | GABA | 3 | 2.5% | 0.3 |
| Pm10 (L) | 3 | GABA | 2 | 1.6% | 0.7 |
| LO_ME_unclear (L) | 1 | Glu | 1.7 | 1.4% | 0.0 |
| Tm2 (L) | 2 | ACh | 1.3 | 1.1% | 0.0 |
| OA-AL2i1 (L) | 1 | unc | 1 | 0.8% | 0.0 |
| T4b (L) | 3 | ACh | 1 | 0.8% | 0.0 |
| T4a (L) | 3 | ACh | 1 | 0.8% | 0.0 |
| DCH (R) | 1 | GABA | 0.7 | 0.5% | 0.0 |
| MeVC11 (R) | 1 | ACh | 0.7 | 0.5% | 0.0 |
| LPi3412 (L) | 2 | Glu | 0.7 | 0.5% | 0.0 |
| Y13 (L) | 2 | Glu | 0.7 | 0.5% | 0.0 |
| Am1 (L) | 1 | GABA | 0.7 | 0.5% | 0.0 |
| LPi2c (L) | 1 | Glu | 0.3 | 0.3% | 0.0 |
| TmY14 (L) | 1 | unc | 0.3 | 0.3% | 0.0 |
| Pm1 (L) | 1 | GABA | 0.3 | 0.3% | 0.0 |
| TmY19b (L) | 1 | GABA | 0.3 | 0.3% | 0.0 |
| Mi10 (L) | 1 | ACh | 0.3 | 0.3% | 0.0 |
| downstream partner | # | NT | conns T4_unclear | % Out | CV |
|---|---|---|---|---|---|
| T4d (L) | 28 | ACh | 49.7 | 28.5% | 0.6 |
| CT1 (R) | 1 | GABA | 19 | 10.9% | 0.0 |
| T4c (L) | 12 | ACh | 13 | 7.5% | 0.7 |
| TmY15 (L) | 6 | GABA | 11 | 6.3% | 0.6 |
| T4b (L) | 11 | ACh | 9.3 | 5.4% | 0.6 |
| TmY18 (L) | 6 | ACh | 6.7 | 3.8% | 0.6 |
| T2 (L) | 5 | ACh | 6.7 | 3.8% | 0.4 |
| Y3 (L) | 2 | ACh | 5.3 | 3.1% | 0.2 |
| Mi4 (L) | 5 | GABA | 5 | 2.9% | 0.9 |
| Pm1 (L) | 3 | GABA | 4 | 2.3% | 0.5 |
| Mi10 (L) | 2 | ACh | 4 | 2.3% | 0.5 |
| Mi1 (L) | 3 | ACh | 3.7 | 2.1% | 0.3 |
| C2 (L) | 6 | GABA | 3.7 | 2.1% | 0.5 |
| T4a (L) | 7 | ACh | 3.3 | 1.9% | 0.3 |
| Am1 (L) | 1 | GABA | 3 | 1.7% | 0.0 |
| TmY14 (L) | 3 | unc | 3 | 1.7% | 0.5 |
| Y12 (L) | 2 | Glu | 2.7 | 1.5% | 0.2 |
| Tm3 (L) | 5 | ACh | 2.7 | 1.5% | 0.3 |
| TmY19a (L) | 2 | GABA | 2.3 | 1.3% | 0.1 |
| TmY19b (L) | 1 | GABA | 1.7 | 1.0% | 0.0 |
| Mi9 (L) | 2 | Glu | 1.7 | 1.0% | 0.2 |
| MeLo9 (L) | 1 | Glu | 1.7 | 1.0% | 0.0 |
| T3 (L) | 3 | ACh | 1.7 | 1.0% | 0.3 |
| TmY5a (L) | 1 | Glu | 1.3 | 0.8% | 0.0 |
| MeVPMe2 (L) | 1 | Glu | 1 | 0.6% | 0.0 |
| T2a (L) | 1 | ACh | 1 | 0.6% | 0.0 |
| MeVPLp2 (L) | 1 | Glu | 1 | 0.6% | 0.0 |
| MeLo8 (L) | 1 | GABA | 1 | 0.6% | 0.0 |
| Mi13 (L) | 1 | Glu | 0.7 | 0.4% | 0.0 |
| Tm12 (L) | 1 | ACh | 0.7 | 0.4% | 0.0 |
| Pm7 (L) | 1 | GABA | 0.7 | 0.4% | 0.0 |
| C3 (L) | 2 | GABA | 0.7 | 0.4% | 0.0 |
| Tm2 (L) | 1 | ACh | 0.3 | 0.2% | 0.0 |
| Tm4 (L) | 1 | ACh | 0.3 | 0.2% | 0.0 |
| Pm2a (L) | 1 | GABA | 0.3 | 0.2% | 0.0 |
| Pm3 (L) | 1 | GABA | 0.3 | 0.2% | 0.0 |